SPDR S&P Biotech ETF
201 hedge funds and large institutions have $2.32B invested in SPDR S&P Biotech ETF in 2016 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 64 increasing their positions, 56 reducing their positions, and 34 closing their positions.
Holders
201
Holders Change
+6
Holders Change %
+3.08%
% of All Funds
5.37%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.05%
New
43
Increased
64
Reduced
56
Closed
34
Calls
$539M
Puts
$880M
Net Calls
-$341M
Net Calls Change
-$69.5M
Top Buyers
| 1 |
1
Citigroup
New York
|
$312M |
| 2 |
2
BNP Paribas Financial Markets
Paris,
France
|
$213M |
| 3 |
SG
3
Societe Generale
|
$26.6M |
| 4 |
RG
4
Redmile Group
San Francisco,
California
|
$26.6M |
| 5 |
HI
5
Honeywell International
Charlotte,
North Carolina
|
$20.6M |
Top Sellers
| 1 |
1
Goldman Sachs
New York
|
$427M |
| 2 |
2
Morgan Stanley
New York
|
$219M |
| 3 |
3
JPMorgan Chase & Co
New York
|
$127M |
| 4 |
4
Bank of America
Charlotte,
North Carolina
|
$163M |
| 5 |
5
Millennium Management
New York
|
$0 |
